Christophe Cataisson

Dr. Christophe Cataisson

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DODiana Ovejero
Diana Ovejero
ZMZachary Michel
Zachary Michel
CCChristophe Cataisson
Christophe Cataisson
ASAmanda Saikali
Amanda Saikali
RGRebeca Galisteo
Rebeca Galisteo
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a mosaic RASopathy characterized by the association of dysplastic skeletal lesions, congenital skin nevi of epidermal and/or melanocytic origin, and FGF23-mediated hypophosphatemia. The primary physiological source of circulating FGF23 is bone cells. However, several reports have suggested skin lesions as the source of excess FGF23 in CSHS. Consequently, without convincing evidence of efficacy, many patients with CSHS have undergone painful removal of cutaneous lesions in an effort to normalize blood phosphate levels. This study aims to elucidate whether the source of FGF23 excess in CSHS is RAS mutation–bearing bone or skin lesions. Toward this end, we analyzed the expression and activity of Fgf23 in two mouse models expressing similar HRAS/Hras activating mutations in a mosaic-like fashion in either bone or epidermal tissue. We found that HRAS hyperactivity in bone, not skin, caused excess of bioactive intact FGF23, hypophosphatemia, and osteomalacia. Our findings support RAS-mutated dysplastic bone as the primary source of physiologically active FGF23 excess in patients with CSHS. This evidence informs the care of patients with CSHS, arguing against the practice of nevi removal to decrease circulating, physiologically active FGF23.

14 May 2024 in Science Signaling
Verified
Journal Article
Closed access
HZHaibo Zhang
Haibo Zhang
ARAbigail Read
Abigail Read
CCChristophe Cataisson
Christophe Cataisson
HYHOWARD H YANG
HOWARD H YANG
WLWei-Chun Lee
Wei-Chun Lee
JLJi Luo
Ji Luo
The Ras–mitogen-activated protein kinase (MAPK) pathway is a major target for cancer treatment. To better understand the genetic pathways that modulate cancer cell sensitivity to MAPK pathway inhibitors, we performed a CRISPR knockout screen with MAPK pathway inhibitors on a colorectal cancer (CRC) cell line carrying mutant KRAS. Genetic deletion of the catalytic subunit of protein phosphatase 6 (PP6), encoded by PPP6C , rendered KRAS - and BRAF -mutant CRC and BRAF -mutant melanoma cells more resistant to these inhibitors. In the absence of MAPK pathway inhibition, PPP6C deletion in CRC cells decreased cell proliferation in two-dimensional (2D) adherent cultures but accelerated the growth of tumor spheroids in 3D culture and tumor xenografts in vivo. PPP6C deletion enhanced the activation of nuclear factor κB (NF-κB) signaling in CRC and melanoma cells and circumvented the cell cycle arrest and decreased cyclin D1 abundance induced by MAPK pathway blockade in CRC cells. Inhibiting NF-κB activity by genetic and pharmacological means restored the sensitivity of PPP6C -deficient cells to MAPK pathway inhibition in CRC and melanoma cells in vitro and in CRC cells in vivo. Furthermore, a R264 point mutation in PPP6C conferred loss of function in CRC cells, phenocopying the enhanced NF-κB activation and resistance to MAPK pathway inhibition observed for PPP6C deletion. These findings demonstrate that PP6 constrains the growth of KRAS - and BRAF -mutant cancer cells, implicates the PP6–NF-κB axis as a modulator of MAPK pathway output, and presents a rationale for cotargeting the NF-κB pathway in PPP6C -mutant cancer cells.

28 October 2022 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
CCChristophe Cataisson
Christophe Cataisson
ALAlex J Lee
Alex J Lee
AZAshley M Zhang
Ashley M Zhang
AMAlicia Mizes
Alicia Mizes
SKSerena Korkmaz
Serena Korkmaz
SYStuart H Yuspa
Stuart H Yuspa
Environmental and molecular carcinogenesis are linked by the discovery that chemical carcinogen induced-mutations in the Hras or Kras genes drives tumor development in mouse skin. Importantly, enhanced expression or allele amplification of the mutant Ras gene contributes to selection of initiated cells, tumor persistence, and progression. To explore the consequences of Ras oncogene signal strength, primary keratinocytes were isolated and cultured from the LSL-HrasG12D and LSL-KrasG12D C57BL/6J mouse models and the mutant allele was activated by adeno-Cre recombinase. Keratinocytes expressing one (H) or two (HH) mutant alleles of HrasG12D, one KrasG12D allele (K), or one of each (HK) were studied. All combinations of activated Ras alleles stimulated proliferation and drove transformation marker expression, but only HH and HK formed tumors. HH, HK, and K sustained long-term keratinocyte growth in vitro, while H and WT could not. RNA-Seq yielded two distinct gene expression profiles; HH, HK and K formed one cluster while H clustered with WT. Weak MAPK activation was seen in H keratinocytes but treatment with a BRAF inhibitor enhanced MAPK signaling and facilitated tumor formation. K keratinocytes became tumorigenic when they were isolated from mice where the LSL-KrasG12D allele was backcrossed from the C57BL/6 onto the FVB/N background. All tumorigenic keratinocytes but not the non-tumorigenic precursors shared a common remodeling of matrisomal gene expression that is associated with tumor formation. Thus, RAS oncogene signal strength determines cell-autonomous changes in initiated cells that are critical for their tumor forming potential.

13 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DMDaniel W. McVicar
Daniel W. McVicar
HKHeba Al Khamici
Heba Al Khamici
AMAleksandra M Michalowski
Aleksandra M Michalowski
JSJeffery Subleski
Jeffery Subleski
CCChristophe Cataisson
Christophe Cataisson
SYStuart Yuspa
Stuart Yuspa
The Chloride Intracellular Channel-4 (CLIC4) is one of six highly conserved proteins in the CLIC family that share high structural homology with glutathione-S-transferase (GST)-omega in the GST superfamily. While CLIC4 is a multifunctional protein that resides in multiple cellular compartments, the discovery of its enzymatic glutaredoxin-like activity in vitro suggested that it could be one of the essential oxidoreductases in cells. Here we show that macrophages lacking Clic4 display a variety of phenotypes including a failure to sustain cytokine production and reduced phagocytosis suggesting a role for Clic4 in metabolic fitness. Null cells have elevated levels of ROS as well as defective cellular energetics and reduced ATP levels. Mechanistically we find that stimulated Clic4 null cells have exacerbated expression of the negative regulator of mitochondrial ROS, UCP2. Accordingly, inhibition of UCP2 restores macrophage energetics and phagocytic activity in vitro and in vivo. We propose a model where Clic4 restrains UCP2 expression by dampening cellular ROS levels thereby preserving the mitochondrial function necessary for highly energetic activities including sustained cytokine production and phagocytosis. Our findings raise the possibility of targeting CLIC4 to induce macrophage hypophagia as a mechanism of innate immune exhaustion to improve some essential therapeutic outcomes for inflammatory diseases and related cancers.

11 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SDSonja Dorfer
Sonja Dorfer
JRJulia Maria Ressler
Julia Maria Ressler
KRKatharina Riebenbauer
Katharina Riebenbauer
SKStefanie Kancz
Stefanie Kancz
KPKim Purkhauser
Kim Purkhauser
AHAlessandra Handisurya
Alessandra Handisurya
The development of keratinocytic skin tumors, presumably attributable to paradoxical activation of the MAPK pathway, represents a relevant side effect of targeted therapies with BRAF inhibitors (BRAFis). The role of cutaneous papillomavirus infection in BRAFi-associated skin carcinogenesis, however, is still inconclusive. Employing the Mus musculus papillomavirus 1 (MmuPV1) skin infection model, the impact of BRAFis and UVB exposure on papillomavirus induced skin tumorigenesis was investigated in immunocompetent FVB/NCrl mice. Systemic BRAF inhibition in combination with UVB light induced skin tumors in 62% of the MmuPV1-infected animals. In contrast, significantly fewer tumors were observed in the absence of either BRAF inhibition, UVB irradiation or virus infection, as demonstrated by lesional outgrowth in 20%, 5% and 0% of the mice, respectively. Combinatory exposure to BRAFis and UVB favored productive viral infection, which was shown by high numbers of MmuPV1 genome copies and E1^E4 spliced transcripts and an abundance of E6/E7 oncogene mRNA and viral capsid proteins. BRAF inhibition, but not viral infection or UVB light, activated ERK1/2, whereas γH2AX expression, inducible by UVB light, remained unaltered by BRAFis. These results provide experimental evidence that BRAF inhibition and UVB irradiation synergistically promote MmuPV1-induced skin tumor development in vivo. This indicates an alternative pathway by which papillomavirus skin infection may contribute to BRAFi-associated skin tumorigenesis.